Default company panoramic image
Logo

Sapientia Pharmaceuticals Inc.

SPI will develop novel therapeutics for a severe orphan disease with no approved therapy and estimated peak sales of over $1B

  • Stage Concept Only
  • Industry Biotechnology
  • Location Havertown, PA, USA
  • Currency USD
  • Founded September 2012
  • Employees 0
  • Website sapientiapharma.com

Company Summary

Systemic Sclerosis is a progressive, fibrotic disease with no approved therapies and ~90,000 cases in the US alone. Sapientia Pharmaceuticals has identified small molecules that act on the fibrosis and vasculopathy of SSc. SPI anticipates filing an Investigational New Drug Applications within 2 years with the total time to marketing authorization 7-9 years. Peak year sales in excess of $1-2B are estimated for a small molecule treatment for SSc.

Team

  • Default avatar
    William V Williams
    Founder

    Dr. Williams served as head of rheumatology research at University of Pennsylvania with over 100 peer reviewed publications. At GlaxoSmithKline he was Head of Experimental Medicine and VP of Clinical Pharmacology. As VP of Exploratory Development at Incyte he brought over a dozen compounds into the clinic and established proof-of-concept for compounds in multiple disease areas including rheumatoid arthritis, psoriasis and diabetes.

  • Default avatar
    James Hoffman
    Founder

    Mr. Hoffman has over 20 years’ experience in the pharmaceutical industry. He worked in the laboratory of Dr. Bryan Brewer at the NIH. At Merck and 3-D Pharmaceuticals he focused his efforts on receptor- based peptidomimetics and structure based drug design. At GSK he led a team of medicinal chemists that developed novel, broad-spectrum antibiotics and progressed it into the clinic. Mr. Hoffman has a Master’s Degree in Business Administration.

  • Default avatar
    Douglas Faller
    Scientific Founder

    Professor of Medicine, Pediatrics, Biochemistry, Microbiology, Pathology and Laboratory Medicine; Vice-Chairman, Division of Medicine, and Director of the Cancer Center; Boston University School of Medicine. Dr. Faller is a recognized international expert in biochemistry, cell biology, nanomedicine, hematology and oncology. He has founded several biotechnology companies, including HemaQuest which is currently in phase 3 clinical trials.

  • Default avatar
    Robert Michael Williams
    Scientific Founder

    University Distinguished Professor of Chemistry, Colorado State University; Recipient, 2011 Ernest Guenther Award in the Chemistry of Natural Products. Dr. Williams is a recognized international expert in organic synthesis of pharmacologically active molecules. Dr. Williams is a consultant for many successful biotechnology companies including HemaQuest, Xcyte and Microcide Pharmaceuticals.

Advisors

  • Default avatar
    John Limongelli
    Lawyer
    Unconfirmed
    Default avatar
    Martin Schmeig
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Founders
    Unconfirmed